Group 1: Overseas Business Performance - The gross margin for the company's overseas business is approximately 50%, which is higher than that of the domestic market [1] - There is a significant growth in opportunities and orders in the overseas market, prompting the company to enhance its international strategy [1] - The revenue from oral solid dosage equipment and intelligent factory segments remains the mainstay of overseas business [1] Group 2: Market Competition Strategy - The company is responding to intense domestic market competition by focusing on customer needs and maintaining a customized, international, and diversified operational strategy [2] - Continuous investment in R&D is aimed at solidifying technological advantages while improving operational quality [2] - The company plans to deepen its core pharmaceutical equipment business and enhance product differentiation and reliability [2] Group 3: Robotics Business Development - The robotics business is operated through a subsidiary, Zhejiang Wantusi Rui Robotics Co., Ltd., which specializes in dedicated robots and software products [2] - The main products include autonomous mobile robots and four-way shuttle robots, primarily serving the pharmaceutical and food industries [2] - The company is actively optimizing its product system and expanding application scenarios [2] Group 4: Cash Flow Improvement - The improvement in operating cash flow is attributed to refined financial management, increased collection efforts, and effective execution of quality enhancement measures [2] - The company focuses on comprehensive control from contract initiation to accounts receivable, optimizing customer structure and targeting high-quality clients [2]